BNB Plus Corp., formerly Applied DNA Sciences, Inc., is a digital asset treasury (DAT) company that has adopted BNB, the native cryptocurrency of the Binance blockchain ecosystem, as its primary reserve asset. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.

Employees

Sector

Investment Management & Fund Operators

More about the company

05-26	BNB Plus Corp. announced that it expects to receive $5 million in funding from Silvermine Capital Advisors, LLC, Off The Chain Capital, LLC	CI
05-16	BNB Plus Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI

Market Cap	2.59M 2.26M 2.08M 1.94M 3.68M 247M 3.74M 25.03M 9.7M 121M 9.73M 9.52M 417M	P/E 2024 *	-	P/E 2025	-0.03x
Enterprise Value	1.12M 976K 896K 835K 1.58M 106M 1.61M 10.79M 4.18M 52.13M 4.19M 4.1M 180M	EV / Sales 2024	0.29x	EV / Sales 2025	1.65x
Free-Float	90.59%	Yield 2024 *	-	Yield 2025	-

05-26	BNB Plus Corp. announced that it expects to receive $5 million in funding from Silvermine Capital Advisors, LLC, Off The Chain Capital, LLC	CI
05-16	BNB Plus Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-21	BNB Plus Corp Announces Review of Strategic Alternatives to Maximize Shareholder Value	CI
03-25	Comstock MultiChain Fund, L P Engages with BNB Plus Corp	CI
02-13	BNB Plus Corp. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-05	BNB Plus Corp. Appoints James Haft as Independent Director and Nominating Committee Member, Effective February 2, 2026	CI
01-23	BNB Plus Corp. Announces Resignation of Director Elizabeth M. Schmalz Shaheen, Effective January 15, 2026	CI
01-05	BNB Plus Corp. Receives USD 1.2 Million Accelerated LineaDNA? Order	CI
01-05	Bnb Plus Corp receives $1.2M Accelerated Lineadna(TM) order	RE
12-22	BNB Plus Corp. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-18	BNB Plus Corp. Announces Largest Ever Shipment of LineaDNA	CI
11-17	Applied DNA rebrands as BNB Plus Corp., elects Josh Kruger as chairman of the board	RE
11-13	Applied DNA Sciences, Inc has Changed its Name to BNB Plus Corp	CI

10/06/24	HC Wainwright Adjusts Applied DNA Sciences Price Target to $1.50 From $7, Maintains Buy Rating	MT
14/05/24	Maxim Downgrades Applied DNA Sciences to Hold From Buy	MT
08/12/23	HC Wainwright Cuts Price Target on Applied DNA Sciences to $2 From $4, Keeps Buy Rating	MT
14/08/23	HC Wainwright Adjusts Price Target on Applied DNA Sciences to $4 From $5, Keeps Buy Rating	MT
15/12/22	HC Wainwright Trims Price Target on Applied DNA Sciences Inc to $5 From $8, Maintains Buy Rating	MT

05-26	BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing	BU
05-16	BNB Plus: Fiscal Q2 Earnings Snapshot	AQ
04-23	BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order	BU
04-20	BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value	BU
03-18	BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform	BU

Applied DNA Sciences Inc Stock OTC Bulletin Board

Stocks

US03815U1025

Investment Management & Fund Operators

Valuation: Applied DNA Sciences Inc

Latest news : Applied DNA Sciences Inc

Analysts' recommendations: Applied DNA Sciences Inc

Press Releases: Applied DNA Sciences Inc

News in other languages: Applied DNA Sciences Inc

Managers and Directors: Applied DNA Sciences Inc

Investment Management

Financials

Company Profile

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

02/03/20	Applied DNA Sciences : informe des avancées de la collaboration avec Takis Biotech concernant le COVID-19 et de la conception de 4 candidats vaccins LinearDNA™ au stade préclinique
02/03/20	Aktuelle Meldung von Applied DNA Sciences zur COVID-19-Kooperation mit Takis Biotech: vier präklinische LinearDNA™-Impfstoffkandidaten entwickelt
29/10/18	Applied DNA Sciences : GHCL, un acteur mondial du linge de maison, crée "CIRKULARITY", une plateforme de marques inspirée par le linge de lit "REKOOP" en polyester recyclé durable et traçable
29/10/18	Applied DNA Sciences : GHCL, azienda internazionale di tessuti per la casa, crea “CIRKULARITY”, una piattaforma di marchi ispirata da “REKOOP”, biancheria in poliestere riciclato, sostenibile e tracciabile
29/10/18	Applied DNA Sciences : GHCL, weltweiter Anbieter von Heimtextilien, gründet die Markenplattform „CIRKULARITY“, inspiriert von „REKOOP“, der Lösung für nachhaltige, rückverfolgbare, recycelte Polyester-Bettwäsche

Manager	Title	Age	Since
Clay Shorrock CEO	Chief Executive Officer	43	29/09/2025
Beth Jantzen DFI	Director of Finance/CFO	49	15/02/2015
Patrick Horsman CIO	Chief Investment Officer	47	01/10/2025

Director	Title	Age	Since
Yacov Shamash BRD	Director/Board Member	76	17/03/2006
Judy Murrah CHM	Chairman	68	18/06/2025
Joseph Ceccoli BRD	Director/Board Member	62	03/12/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BLACKSTONE INC.	+2.70%	+7.53%	-20.04%	+32.06%	96.44B
KKR & CO. INC.	+1.38%	+1.28%	-30.25%	+67.57%	84.26B
ARES MANAGEMENT CORPORATION	+2.88%	+3.94%	-34.32%	+21.33%	26.36B
AMUNDI	+0.87%	+4.08%	+25.34%	+59.12%	20.01B
FRANKLIN RESOURCES, INC.	+0.15%	+4.47%	+37.60%	+27.70%	17.72B
THE CARLYLE GROUP INC.	+1.18%	+2.22%	-21.34%	+34.05%	15.42B
ARES CAPITAL CORPORATION	+0.38%	+4.11%	-15.86%	-0.32%	13.45B
PERSHING SQUARE INC.	-1.76%	+9.45%	-	-	12.97B
HDFC ASSET MANAGEMENT COMPANY LIMITED	+1.71%	+7.61%	+11.20%	+145.45%	12.42B
Average	+1.05%	+4.66%	-5.96%	+48.37%	33.23B
Weighted average by Cap.	+1.65%	+4.59%	-16.13%	+46.66%

	2024	2025
Net sales	3.43M 3M 2.75M 2.57M 4.87M 327M 4.95M 33.15M 12.85M 160M 12.88M 12.6M 552M	2.14M 1.87M 1.71M 1.6M 3.03M 203M 3.08M 20.64M 8M 99.78M 8.02M 7.85M 344M
Net income	-6.99M -6.11M -5.61M -5.23M -9.92M -666M -10.09M -67.55M -26.18M -327M -26.26M -25.68M -1.13B	-15.16M -13.25M -12.16M -11.34M -21.51M -1.44B -21.87M -146M -56.76M -708M -56.93M -55.69M -2.44B
Net Debt	-5.69M -4.97M -4.57M -4.26M -8.07M -542M -8.21M -54.99M -21.31M -266M -21.37M -20.91M -916M	-1.47M -1.29M -1.18M -1.1M -2.09M -140M -2.13M -14.25M -5.52M -68.85M -5.54M -5.42M -237M